AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36152527 — intervention group
Group type: COMPARATOR
Intervention: Self-stretching
Number of subjects: 38
Study 34453504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electro-acupuncture
Number of subjects: 54
Study 34453504 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 54
Study 33528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss following RYGB
Number of subjects: 1020
Study 32669410 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference cut points of >102 cm in men
Number of subjects: 16289
Study 32669410 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference cut points of >97 cm in women
Number of subjects: 16289
Study 32669410 — intervention group
Group type: COMPARATOR
Intervention: Current JIS criteria for metabolic syndrome
Number of subjects: 16289
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.54 μg/kg/min)
Number of subjects: 78
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.08 μg/kg/min)
Number of subjects: 78
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol (2 μg/kg/min)
Number of subjects: 78
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 78
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 78
Study 36172051 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol
Number of subjects: 78
Study 32540434 — intervention group
Group type: EXPERIMENTAL
Intervention: NOBLE trial
Number of subjects: 0
Study 32540434 — intervention group
Group type: COMPARATOR
Intervention: EXCEL trial
Number of subjects: 0
Study 32540434 — intervention group
Group type: EXPERIMENTAL
Intervention: MITRA-FR trial
Number of subjects: 0
Study 32540434 — intervention group
Group type: COMPARATOR
Intervention: COAPT trial
Number of subjects: 0
Study 32124657 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing a novice model
Number of subjects: 156
Study 32124657 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing an expert model
Number of subjects: 156
Study 32124657 — intervention group
Group type: COMPARATOR
Intervention: Learning without a model
Number of subjects: 156
Study 32124657 — intervention group
Group type: COMPARATOR
Intervention: Physical practice
Number of subjects: 156
Study 32533796 — intervention group
Group type: COMPARATOR
Intervention: ATTACH intervention
Number of subjects: 20
Study 35997325 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (FPV) 1800 mg BID on Day 1 and 800 mg BID for 5-14 days thereafter
Number of subjects: 93
Study 35997325 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (FPV)
Number of subjects: 93
Study 35997325 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive care only)
Number of subjects: 93
Study 33781704 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal (Group 2) at 3-4 days postoperatively
Number of subjects: 49
Study 33781704 — intervention group
Group type: COMPARATOR
Intervention: Output-based drain removal (Group 1)
Number of subjects: 49
Study 32111892 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB-before-PPV
Number of subjects: 89
Study 32111892 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 89
Study 32111892 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB
Number of subjects: 89
Study 32111892 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 89
Study 32111892 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (PPV)
Number of subjects: 89
Study 32111892 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB injections
Number of subjects: 89
Study 32631958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan therapy (table fan)
Number of subjects: 1
Study 32631958 — intervention group
Group type: COMPARATOR
Intervention: Fan therapy
Number of subjects: 1
Study 34247100 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin-removed recombinant MaINTL (rMaINTL) protein
Number of subjects: 0
Study 34247100 — intervention group
Group type: COMPARATOR
Intervention: GST-tag proteins
Number of subjects: 0
Study 34958382 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 5 μg or 10 μg of a SARS-CoV-2 inactivated vaccine
Number of subjects: 500
Study 34958382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 34262261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg frovatriptan succinate tablet (single-dose)
Number of subjects: 24
Study 34262261 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg frovatriptan succinate tablet (single-dose)
Number of subjects: 24
Study 34262261 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg frovatriptan succinate tablet (single-dose)
Number of subjects: 24
Study 34262261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg frovatriptan succinate tablet (multiple-dose, 12 times in 7 days)
Number of subjects: 24
Study 32241790 — intervention group
Group type: EXPERIMENTAL
Intervention: Labral repair
Number of subjects: 114
Study 32241790 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 114
Study 32241790 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 114
Study 36094457 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NMES (n = 21)
Number of subjects: 64
Study 36094457 — intervention group
Group type: COMPARATOR
Intervention: Sham NMES (n = 8)
Number of subjects: 64
Study 34411221 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS (implants with surface modified by double acid‐etching and sandblasting)
Number of subjects: 20
Study 34411221 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-H (implants with surface modified by double acid‐etching and sandblasting, stored in 0.9% saline solution)
Number of subjects: 20
Study 34411221 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 20
Study 32948816 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw mulching practices
Number of subjects: 0
Study 35107429 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (EC) with continuous glucose monitoring and low-carbohydrate nutrition counseling (<100 g/day)
Number of subjects: 1584
Study 35107429 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1584
Study 34805204 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Number of subjects: 84
Study 34805204 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 84
Study 35699263 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy Program for Management of Chronic Cough (TMCC)
Number of subjects: 11
Study 35699263 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Vocal Rehabilitation Program (CVRP)
Number of subjects: 11
Study 33764863 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture for chondral defects (Group 1)
Number of subjects: 55
Study 33764863 — intervention group
Group type: COMPARATOR
Intervention: Defect debridement procedure only (Group 2)
Number of subjects: 55
Study 36397102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review, patient counselling, and information transmission to general practitioners and community pharmacies after discharge
Number of subjects: 216
Study 36397102 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 33086438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks (q12w)
Number of subjects: 399
Study 33086438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks (q8w)
Number of subjects: 399
Study 33086438 — intervention group
Group type: COMPARATOR
Intervention: Combined ustekinumab
Number of subjects: 399
Study 33086438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 35477563 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri (Prodentis®‐lozenges, DSM 17938, ATCC PTA 5289)
Number of subjects: 68
Study 35477563 — intervention group
Group type: COMPARATOR
Intervention: Control lozenges
Number of subjects: 68
Study 33858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 228
Study 33858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 228
Study 33858775 — intervention group
Group type: EXPERIMENTAL
Intervention: HEI‐2015 total scores
Number of subjects: 228
Study 36074747 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper oxide wire particles (COWP) 2 g administered orally
Number of subjects: 57
Study 36074747 — intervention group
Group type: COMPARATOR
Intervention: Placebo control capsule
Number of subjects: 57
Study 34078331 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical patency maintained with a size 10 K-file during conventional hand filing step-back shaping procedure.
Number of subjects: 160
Study 34078331 — intervention group
Group type: COMPARATOR
Intervention: Non-patency group (control).
Number of subjects: 160
Study 34078331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital teeth of patency-maintained group treated in multiple visits.
Number of subjects: 160
Study 34078331 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain.
Number of subjects: 160
Study 34791074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (3g once daily for 10 days)
Number of subjects: 97
Study 34791074 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (0.5g twice daily for 10 days)
Number of subjects: 97
Study 32711957 — intervention group
Group type: EXPERIMENTAL
Intervention: L + ICE (ice slurry ingestion)
Number of subjects: 10
Study 32711957 — intervention group
Group type: EXPERIMENTAL
Intervention: M + ICE (ice slurry ingestion)
Number of subjects: 10
Study 32711957 — intervention group
Group type: COMPARATOR
Intervention: L + AMB (ambient water ingestion)
Number of subjects: 10
Study 32711957 — intervention group
Group type: COMPARATOR
Intervention: M + AMB (ambient water ingestion)
Number of subjects: 10
Study 34976613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (information and attendance incentive)
Number of subjects: 1320
Study 34976613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (information, attendance incentives, personalized support)
Number of subjects: 1320
Study 34976613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1320
Study 34976613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users of the facility
Number of subjects: 1320
Study 34976613 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency and duration of promotion
Number of subjects: 1320
Study 34976613 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular attendance
Number of subjects: 1320
Study 35265302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) combined with conventional physical therapy
Number of subjects: 110
Study 35265302 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 110
Study 32299355 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (10 μg/ml)
Number of subjects: 0
Study 32299355 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly (I:C) (10 μg/ml)
Number of subjects: 0
Study 32299355 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated Vibrio harveyi (107 cell/ml)
Number of subjects: 0
Study 32299355 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS dose-increased treatment (0, 10, 20, and 50 μg/ml)
Number of subjects: 0
Study 33419788 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimel 16% manuka honey eye-drops
Number of subjects: 59
Study 33419788 — intervention group
Group type: COMPARATOR
Intervention: Regular lubricants (control group)
Number of subjects: 59
Study 34574794 — intervention group
Group type: EXPERIMENTAL
Intervention: multisport enriched PE
Number of subjects: 181
Study 34574794 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 181
Study 35595501 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS‐BL‐guided intensive HF management
Number of subjects: 318
Study 35595501 — intervention group
Group type: COMPARATOR
Intervention: Conventional HF management
Number of subjects: 318
Study 33839197 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 111
Study 33839197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 32129194 — intervention group
Group type: COMPARATOR
Intervention: Alpha-keto analogue (600 mg tablet three times a day)
Number of subjects: 150
Study 32129194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-keto analogue (600 mg tablet three times a day) + Nigella sativa oil (2.5 mL, per orally, once daily) for 12 weeks
Number of subjects: 150
Study 36057171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 114700
Study 36057171 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 114700
Study 36057171 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance to colonoscopy after positive FIT
Number of subjects: 114700
Study 34755007 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly minodronate (MIN group)
Number of subjects: 164
Study 34755007 — intervention group
Group type: COMPARATOR
Intervention: Active vitamin D (VD group)
Number of subjects: 164
Study 33324264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette 1 (patient receiving MMT)
Number of subjects: 1066
Study 33324264 — intervention group
Group type: COMPARATOR
Intervention: Vignette 2 (patient receiving amlodipine treatment)
Number of subjects: 1066
Study 34875529 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 40
Study 34875529 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PC)
Number of subjects: 40
Study 33420819 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic rocuronium
Number of subjects: 40
Study 33420819 — intervention group
Group type: COMPARATOR
Intervention: Original rocuronium
Number of subjects: 40
Study 35706006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra for 24 weeks
Number of subjects: 102
Study 35706006 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 102
Study 32506845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (25-min, ten one-minute intervals at 85% heart-rate reserve)
Number of subjects: 9
Study 32506845 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (45-min at 50% heart-rate reserve)
Number of subjects: 9
Study 32506845 — intervention group
Group type: COMPARATOR
Intervention: Control day (30-min quiet rest)
Number of subjects: 9
Study 35251557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention based on mobile nursing system
Number of subjects: 266
Study 35251557 — intervention group
Group type: COMPARATOR
Intervention: Routine physical examination during pregnancy
Number of subjects: 266
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LC) - <40% energy from carbohydrates
Number of subjects: 0
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LF) - <30% energy from fat
Number of subjects: 0
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss
Number of subjects: 0
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual carbohydrate intake at the end of the study
Number of subjects: 0
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual fat intake at the end of the study
Number of subjects: 0
Study 32885229 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake changes
Number of subjects: 0
Study 32358397 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium triplex)
Number of subjects: 60
Study 34477175 — intervention group
Group type: EXPERIMENTAL
Intervention: LF rTMS + MI + active ES
Number of subjects: 17
Study 34477175 — intervention group
Group type: COMPARATOR
Intervention: LF rTMS + MI + sham ES
Number of subjects: 17
Study 32315869 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 241
Study 32315869 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 241
Study 34498307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract tablets
Number of subjects: 44
Study 34498307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 33475546 — intervention group
Group type: EXPERIMENTAL
Intervention: OneShape file
Number of subjects: 60
Study 33475546 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Next rotary instrument
Number of subjects: 60
Study 33983526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Transport technique (BT)
Number of subjects: 25
Study 33983526 — intervention group
Group type: COMPARATOR
Intervention: Masquelet technique (MT)
Number of subjects: 25
Study 35770557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on fifteen anxiety‐related points
Number of subjects: 20
Study 35770557 — intervention group
Group type: COMPARATOR
Intervention: Control group received acupuncture on fifteen points unrelated to anxiety
Number of subjects: 20
Study 32814640 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination during pregnancy
Number of subjects: 1752
Study 32814640 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 1752
Study 35931103 — intervention group
Group type: EXPERIMENTAL
Intervention: IMGX003 (1200 mg)
Number of subjects: 50
Study 35931103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32748473 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (40 g/day)
Number of subjects: 110
Study 36055798 — intervention group
Group type: EXPERIMENTAL
Intervention: o‐RUTF
Number of subjects: 129
Study 36055798 — intervention group
Group type: COMPARATOR
Intervention: s‐RUTF
Number of subjects: 129
Study 34241955 — intervention group
Group type: EXPERIMENTAL
Intervention: Father involvement during pregnancy and postnatal
Number of subjects: 212
Study 32404096 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary rehabilitation programme (supervised and self-managed exercise, dietary counselling, and education)
Number of subjects: 120
Study 32404096 — intervention group
Group type: COMPARATOR
Intervention: Standard survivorship care
Number of subjects: 120
Study 35628300 — intervention group
Group type: EXPERIMENTAL
Intervention: DI + thigh cuff
Number of subjects: 18
Study 35628300 — intervention group
Group type: COMPARATOR
Intervention: Control (only DI)
Number of subjects: 18
Study 33355646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib with gemcitabine (A)
Number of subjects: 90
Study 33355646 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib without gemcitabine (B)
Number of subjects: 90
Study 35918106 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat three times weekly
Number of subjects: 407
Study 35918106 — intervention group
Group type: COMPARATOR
Intervention: Conventional epoetin
Number of subjects: 407
Study 35918106 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 407
Study 35918106 — intervention group
Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 407
Study 33125769 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 191
Study 33125769 — intervention group
Group type: COMPARATOR
Intervention: Observation without treatment (OBS)
Number of subjects: 191
Study 34036760 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (I Love You method), 15 minutes before feeding, twice a day for 5 days
Number of subjects: 0
Study 34036760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 0
Study 32147198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts (Nuts)
Number of subjects: 155
Study 32147198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 155
Study 32147198 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 155
Study 35940492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 0
Study 35940492 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 0
Study 33549600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral information plus an information pamphlet (Group 1; n = 45)
Number of subjects: 90
Study 33549600 — intervention group
Group type: COMPARATOR
Intervention: Oral information alone (Group 2; n = 45)
Number of subjects: 90
Study 32468955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib
Number of subjects: 291
Study 32468955 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 291
Study 35787693 — intervention group
Group type: EXPERIMENTAL
Intervention: Solutech (10.0 mg Δ9‐THC, 9.76 mg CBD)
Number of subjects: 32
Study 35787693 — intervention group
Group type: COMPARATOR
Intervention: MCT-oil (10.0 mg Δ9‐THC, 9.92 mg CBD)
Number of subjects: 32
Study 33502237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense neoadjuvant androgen deprivation therapy followed by radical prostatectomy
Number of subjects: 117
Study 33502237 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceptional pathological response (0-5 mm residual tumor)
Number of subjects: 117
Study 33502237 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (patients without exceptional pathological response)
Number of subjects: 117
Study 33502237 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone recovery post-treatment
Number of subjects: 117
Study 33189627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 27918
Study 33189627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 27918
Study 33189627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (in participants with diabetes)
Number of subjects: 27918
Study 33189627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (in diabetes-free participants)
Number of subjects: 27918